Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Underestimating Synergies with Cephalon
Tweet
Share
E-mailGet Alerts VRX Hot Sheet
Price: $23.40 --0%
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
0 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Valeant Pharmaceuticals (NYSE: VRX), PT under review.
Canaccord analyst says, "Valeant’s conference call on its hostile bid for Cephalon (Nasdaq: CEPH) did little to change our positive view of potential synergies from this transaction. However, we do believe that management may be underestimating cost savings that could be realized if the deal is consummated. At the same time, we have become marginally more comfortable with the potential debt levels for Valeant should the transaction close, as well as the company’s strategy to pay this down. While not included in our analysis, we also believe that Valeant could generate revenue synergies with Cephalon’s products."
For more ratings news on Valeant Pharmaceuticals click here and for the rating history of Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $50.08 yesterday.
Canaccord analyst says, "Valeant’s conference call on its hostile bid for Cephalon (Nasdaq: CEPH) did little to change our positive view of potential synergies from this transaction. However, we do believe that management may be underestimating cost savings that could be realized if the deal is consummated. At the same time, we have become marginally more comfortable with the potential debt levels for Valeant should the transaction close, as well as the company’s strategy to pay this down. While not included in our analysis, we also believe that Valeant could generate revenue synergies with Cephalon’s products."
For more ratings news on Valeant Pharmaceuticals click here and for the rating history of Valeant Pharmaceuticals click here.
Shares of Valeant Pharmaceuticals closed at $50.08 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Deere (DE) PT Raised to $585 at JPMorgan
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
Create E-mail Alert Related Categories
Analyst Comments, Mergers and AcquisitionsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
